Dr. Philip McCarthy on the Phase III CALGB-ECOG 100104 Study
 

Background: At a prespecified interim analysis (Dec 2009), the phase 3 CALGB study results surpassed the prespecified superiority boundary (significantly improved progression-free survival for lenalidomide maintenance vs placebo maintenance after stem cell transplant) and the majority of placebo arm patients without progressive disease (PD) crossed over to lenalidomide (LEN) maintenance An updated analysis (cutoff Mar 2015), showed significantly longer overall survival (OS) with LEN maint (HR, 0.56; 95% CI, 0.42-0.76). We examined the effect of LEN vs PBO on OS and PFS from randomization, adjusting for XO effects.

Author(s): Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J Gibson, Edward Allen Stadtmauer, Benjamin Winograd, Paul G. Richardson; Roswell Park Cancer Institute, Buffalo, NY; Duke University School of Medicine, Durham, NC; BresMed, Sheffield, United Kingdom; Celgene Corporation, Summit, NJ; Abramson Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA

Clinical trial information: NCT00114101 (http://clinicaltrials.gov/show/NCT00114101)

ABOUT PHILIP MCCARTHY, MD

Dr. Philip McCarthy is a Professor of Oncology and Internal Medicine and the Director of the Transplant and Cellular Therapy Center at the Roswell Comprehensive Cancer Center in Roswell Park, New York. He also holds the position of Professor of Oncology and Internal Medicine at the Chief of Plasma Cell Disorders and Director of Clinical Research in Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in Buffalo, New York. View Dr. Philip MCarthy’s full biography here (https://www.roswellpark.org/philip-mccarthy). (https://www.roswellpark.org/philip-mccarthy)